The VERTIS-CV trial results, presented at this year's virtual American Diabetes Association (ADA) Scientific Sessions, raise more questions than they answer.
Before we dive into interpreting the implications of these results and the purported cardiovascular (CV) benefits of SGLT2 inhibitors, let's review some commonsense caveats:
We still need to wait for the peer-reviewed publication from VERTIS-CV.
CV outcome trials (CVOTs) are not head-to-head, with numerous study differences, making comparisons difficult.
Nonetheless, the presenters of the VERTIS-CV session asserted that the overall results of this new study are in line with other SGLT2-inhibitor outcome trials, based on a new meta-analysis combining their results with EMPA-REG, CANVAS, CREDENCE, and DECLARE-TIMI 58.
But can clinical decisions be based solely on meta-analyzing such heterogeneous trials? Or should we first consider the overall neutral results (primary and all secondary endpoints) of the CVOT in question? And then, as the next step, compare like-vs-like CVOTs before meta-analyzing a variety of CVOTs and chronic kidney disease outcome trials?
Why did they jump straightaway to comparing and combining apples and oranges?
Comparing Like-vs-Like CVOTs
VERTIS-CV is similar to EMPA-REG in multiple ways. Both trials had similar baseline characteristics and background glucose-lowering and cardioprotective medications, which is expected, given that the enrollment criteria for both studies were limited to secondary prevention populations with
COMMENTARY
VERTIS-CV Results 'Disappoint,' Raise More Questions
Harpreet S. Bajaj, MD, MPH
DisclosuresJuly 02, 2020
The VERTIS-CV trial results, presented at this year's virtual American Diabetes Association (ADA) Scientific Sessions, raise more questions than they answer.
Before we dive into interpreting the implications of these results and the purported cardiovascular (CV) benefits of SGLT2 inhibitors, let's review some commonsense caveats:
We still need to wait for the peer-reviewed publication from VERTIS-CV.
CV outcome trials (CVOTs) are not head-to-head, with numerous study differences, making comparisons difficult.
Nonetheless, the presenters of the VERTIS-CV session asserted that the overall results of this new study are in line with other SGLT2-inhibitor outcome trials, based on a new meta-analysis combining their results with EMPA-REG, CANVAS, CREDENCE, and DECLARE-TIMI 58.
But can clinical decisions be based solely on meta-analyzing such heterogeneous trials? Or should we first consider the overall neutral results (primary and all secondary endpoints) of the CVOT in question? And then, as the next step, compare like-vs-like CVOTs before meta-analyzing a variety of CVOTs and chronic kidney disease outcome trials?
Why did they jump straightaway to comparing and combining apples and oranges?
Comparing Like-vs-Like CVOTs
VERTIS-CV is similar to EMPA-REG in multiple ways. Both trials had similar baseline characteristics and background glucose-lowering and cardioprotective medications, which is expected, given that the enrollment criteria for both studies were limited to secondary prevention populations with
Medscape Diabetes © 2020 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: VERTIS-CV Results 'Disappoint,' Raise More Questions - Medscape - Jul 02, 2020.
Tables
Authors and Disclosures
Authors and Disclosures
Author
Harpreet S. Bajaj, MD, MPH
Research Associate, Leadership Sinai Center for Diabetes, Mount Sinai Hospital; Endocrinologist, LMC Diabetes & Endocrinology, Brampton, Ontario, Canada
Disclosure: Harpreet S. Bajaj, MD, MPH, had disclosed the following relevant financial relationships:
Serve(d) as a speaker or a member of a speakers bureau for: Amgen; AstraZeneca; Boehringer Ingelheim; Janssen; Merck; Novo Nordisk; Sanofi Received research grant from: AstraZeneca; Boehringer Ingelheim; Eli Lilly; Janssen; Merck; Novo Nordisk; Sanofi; Valeant
Received income in an amount equal to or greater than $250 from: Amgen; AstraZeneca; Boehringer Ingelheim; Canadian Collaborative Research Network; CMS Knowledge Translation; Diabetes Canada Scientific Group; Janssen; LMC Healthcare; mdBriefCase; Medscape; Meducom; Merck; Novo Nordisk; Sanofi-Aventis; Valeant